GMP CFR 21 Part 11: Gap Assessment and Remediation Planning

digi — Sat, 15 Nov 2025 08:50:47 +0000

GMP CFR 21 Part 11: Gap Assessment and Remediation Planning Comprehensive Guide to GMP CFR 21 Part 11 Gap Assessment and Remediation Planning Pharmaceutical manufacturing and related regulated industries are governed by stringent data integrity requirements. The GMP CFR 21 Part 11 regulation, issued by the US Food and Drug Administration (FDA), delineates criteria under...

FDA Data Integrity Guidance: Applying Risk-Based Approaches Across Systems

digi — Sat, 15 Nov 2025 08:11:47 +0000

FDA Data Integrity Guidance: Applying Risk-Based Approaches Across Systems Implementing FDA Data Integrity Guidance Through Risk-Based System Prioritisation Data integrity remains a cornerstone of pharmaceutical quality systems globally, underpinning patient safety, product efficacy, and regulatory compliance. The FDA data integrity guidance issued in recent years emphasizes a risk-based approach to managing data through manufacturing, laboratory,...

prioritisation – Pharma GMP

GMP CFR 21 Part 11: Gap Assessment and Remediation Planning

FDA Data Integrity Guidance: Applying Risk-Based Approaches Across Systems